131 related articles for article (PubMed ID: 16611279)
21. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Lee RD; Mulford D; Wu J; Atkinson SN
Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
[TBL] [Abstract][Full Text] [Related]
22. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.
Martínek J; Blum AL; Stolte M; Hartmann M; Verdú EF; Lühmann R; Dorta G; Wiesel P
Aliment Pharmacol Ther; 1999 Jan; 13(1):27-34. PubMed ID: 9892876
[TBL] [Abstract][Full Text] [Related]
23. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH.
Chowers Y; Atarot T; Pratha VS; Fass R
Neurogastroenterol Motil; 2012 May; 24(5):426-31, e208-9. PubMed ID: 22372795
[TBL] [Abstract][Full Text] [Related]
24. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
25. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Hunt RH; Armstrong D; Yaghoobi M; James C; Chen Y; Leonard J; Shin JM; Lee E; Tang-Liu D; Sachs G
Aliment Pharmacol Ther; 2008 Jul; 28(2):187-99. PubMed ID: 18445141
[TBL] [Abstract][Full Text] [Related]
26. The effects of dose and timing of esomeprazole administration on 24-h, daytime and night-time acid inhibition in healthy volunteers.
Wilder-Smith C; Röhss K; Bokelund Singh S; Sagar M; Nagy P
Aliment Pharmacol Ther; 2010 Nov; 32(10):1249-56. PubMed ID: 20955444
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
28. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
[TBL] [Abstract][Full Text] [Related]
29. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
30. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
[TBL] [Abstract][Full Text] [Related]
31. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
32. Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole.
Martínek J; Pantoflícková D; Hucl T; Benes M; Dorta G; Lukás M; Spicák J
Eur J Gastroenterol Hepatol; 2004 May; 16(5):445-50. PubMed ID: 15097035
[TBL] [Abstract][Full Text] [Related]
33. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily.
Hatlebakk JG; Katz PO; Kuo B; Castell DO
Aliment Pharmacol Ther; 1998 Dec; 12(12):1235-40. PubMed ID: 9882032
[TBL] [Abstract][Full Text] [Related]
34. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
Dammann HG; Burkhardt F; Wolf N
Aliment Pharmacol Ther; 1999 Sep; 13(9):1195-203. PubMed ID: 10468701
[TBL] [Abstract][Full Text] [Related]
35. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.
Bell NJ; Hunt RH
Aliment Pharmacol Ther; 1996 Dec; 10(6):897-904. PubMed ID: 8971286
[TBL] [Abstract][Full Text] [Related]
36. Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
Katsube T; Adachi K; Kawamura A; Amano K; Uchida Y; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Aug; 14(8):1049-56. PubMed ID: 10930899
[TBL] [Abstract][Full Text] [Related]
37. [Proton pump inhibitors: Tenatoprazole (TU-199)].
Nakamura T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():650-4. PubMed ID: 11979864
[No Abstract] [Full Text] [Related]
38. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.
Peghini PL; Katz PO; Castell DO
Gastroenterology; 1998 Dec; 115(6):1335-9. PubMed ID: 9834259
[TBL] [Abstract][Full Text] [Related]
39. HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule.
Liu P; Sun B; Lu X; Qin F; Li F
Biomed Chromatogr; 2007 Jan; 21(1):89-93. PubMed ID: 17080510
[TBL] [Abstract][Full Text] [Related]
40. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
Dong H
Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):533-6. PubMed ID: 11798692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
